Four Different Diseases. One Hidden Alarm. And $1.6B+ In Pharma Money Moving Before Most Investors Have Heard Its Name.

EverLife Capital is educational research, not investment advice. I'm not an RIA, broker-dealer, or fund manager. The research tracker referenced is a hypothetical tool I use to test my evaluation method, no real capital, no fund, no client assets. Everything here is educational, impersonal, and not tailored to anyone's situation. See full disclaimer.

If we haven't met: I'm Eric Pemper. I spent twenty-five years building a company before turning my attention full-time to one question, which developments in longevity biotech actually matter, both for understanding the science and for thinking about the field clearly. EverLife Capital is where I do that work in the open. What follows is one issue of it.

Here is something almost no one outside a handful of labs understands yet.

Four age-related diseases, heart disease, Alzheimer's, type 2 diabetes, and gout, look like four separate problems. Different doctors. Different drugs. Different parts of the body.

Growing evidence says they may share part of the same inflammatory machinery. One biological alarm system appears to be involved across all four.

Picture a smoke detector. It is supposed to fire briefly when there is a real threat, then go quiet. Inside your cells sits a biological version of that alarm, called the NLRP3 inflammasome (NLRP3 for short). When working properly, it fires when needed and quiets down afterward. With age and chronic disease, it can become overactive, humming a low, constant alarm that never stops. And that persistent signal appears to feed all four of those conditions.

If that is true, and the science is pointing harder at it every year, then a drug that modulates that pathway might not be relevant to only one disease. If clinical outcomes eventually confirm the biomarker story, drugs aimed at this pathway could have relevance across more than one disease category. That would be a meaningful shift in how these conditions are treated.

Now here is the part that made me pay attention.

Since 2020, large pharmaceutical companies have committed significant capital to NLRP3 and inflammasome-related programs. Roche acquired Inflazome for its oral NLRP3 inhibitor portfolio, and in January 2026 Lilly agreed to acquire Ventyx for about $1.2 billion, a 62% premium to Ventyx's 30-day volume-weighted average trading price ended January 5, 2026, including a pipeline with NLRP3 inhibitors. Together, those two disclosed transactions alone represent more than $1.6 billion in deal value. These were not small academic signals. They were real strategic transactions by large pharmaceutical companies, aimed at inflammation biology that overlaps directly with the NLRP3 field.

When large pharmaceutical companies independently place this much disclosed capital behind the same biology, it suggests they see meaningful potential in it.

Here is what I find remarkable. You can read the financial press every day and barely see this. The deals get covered one at a time, as if they are unrelated. It is still early enough that most investors haven't connected the pattern across these separate deals. Easy to miss. Which is exactly when it is worth understanding.

So why am I the one writing this?

Because for the last few years I've done little else but study this field. I built a 25-question evaluation framework (I call it the 25-Gate framework), and I've run hundreds of longevity biotech companies through it. I built it the expensive way. The first two biotech companies I ever backed went to zero. I trusted the science and forgot to check the company. That mistake cost me real money, and it taught me the lesson this whole publication is built on: in this field, a beautiful idea and a good company are not the same thing. Most of these companies fail. The framework exists to identify the few that may deserve closer study, and, just as important, to keep me honest about what I don't know.

According to DelveInsight's pipeline review, roughly twenty or more companies are working on this pathway. I ran the field through the framework. Most are variations on the same approach. A few look different, but may still depend on the same underlying mechanism. If someone studied several of them, they might think they had diversified, when in reality they had repeated the same biological bet.

One company emerged as the most differentiated candidate under my framework, though it was not the only top-quality name in the group. Why the deciding factor was not quality alone, but fit, is the most useful thing in this issue.

What I will tell you here, in the open, is this: the company the framework flagged for continued observation recently did something most of this field only promises. In early human clinical studies, it reduced a key inflammatory marker, not just in preclinical models.

For Premium members, I break down the two finalists, why the obvious answer was not necessarily the right framework answer, and how the functional-correlation test changed the outcome.

A note on membership: 25% of all membership revenue goes to longevity companies and foundations pushing this science forward. You are not only learning, your membership helps fund the work. I publish where it goes.

7-day free trial.

This publication is impersonal and not tailored to anyone's investment needs. I hold personal equity in two longevity companies, Repair Biotechnologies and Yuva Biosciences; neither is the company discussed below, and I hold no position in it.